Clinical Trial Update: PD-1 + FOLFOXIRI vs CAPOX as Total Neoadjuvant Therapy for pMMR Low Rectal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing PD-1–based total neoadjuvant therapy (PD-1 inhibitor plus FOLFOXIRI) versus CAPOX for microsatellite-stable locally advanced rectal ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Capecitabine (capecitabine)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• PD-1 inhibitor (unspecified)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Locally Advanced Low Rectal Adenocarcinoma, pMMR (Microsatellite Stable Rectal Cancer) | Phase 3 | Status: NOT_YET_RECRUITING